Biomimetic Therapeutics — Technical Presentation (July 2010)
19 slides from Biomimetic Therapeutics's technical presentation, Jul 7, 2010
Slide 1: Economic Evaluation of Direct Costs Associated with Harvesting Autogenous Bone Graft in Foot and Ankle Fusion Surgery
Nicholas A. Abidi, M.D. Kathryn P. Anastassopoulos, M.S. Stacey J. Ackerman, MSE, PhD Economic Evaluation of Direct Costs Associated with Harvesting Autogenous Bone Graft in Foot and Ankle Fusion Surgery
Slide 2: Disclosures
My Disclosures Editorial Board Foot and Ankle Techniques Reviewer: FAI, JBJS, JofTrauma, JAAOS Consultant: Acumed, Arthrex, Biomet, Biomimetic Anastassopoulos and Ackerman - Covance Market Access, Inc. Consultant: BioMimetic Therapeutics Disclosures
Slide 3: Introduction: Foot and ankle arthrodesis commonly performed in the US
Foot and ankle arthrodesis are commonly performed in the US 110,000 procedures per year in US Bone graft is frequently used as an adjunct Iliac Crest Proximal Tibia Distal Tibia Calcaneus Introduction
Slide 4: Introduction: Cost of bone grafting studied in spine literature
The cost of bone grafting has been studied well in the Spine Literature Polly et al, Orthopaedics October, 2003 Cost comparison of BMP-2 vs. ICBG St. John et al, American Journal of Orthopaedics January 2003 Physical and Monetary Costs Associated with Bone Graft Harvesting (ICBG) Introduction
Slide 5: Introduction: No multicenter studies of ICBG and local bone graft costs
No multicenter studies currently which assess direct costs of ICBG and Local Bone Graft (LBG) in foot and ankle arthrodesis procedures We will address ICBG/LBG peri-operative costs in the hospital, outpatient surgery center, post-operative pain and complication management This study is designed to a
Slide 6: Materials and Methods: Surgeon survey
Ten AOFAS/AAOS Surgeons across the country- academic and private practice mixture Average of 14 years experience in foot and ankle arthrodeses and bone grafting Survey instrument mailed out, analyzed by Covance Market Access statisticians Materials and Methods
Slide 7: Materials and Methods: Utilization and resources measured
ICBG and LBG frequency of utilization Additional time-operative, anesthesia, recovery room, admission to the floor-due to graft Additional instrumentation sets utilized for grafting Additional bone grafting materials used to extend autograft and backfill autograft donor site Materials and Methods
Slide 8: Materials and Methods: Practice profile and hospital cost data
Profile of their practices Number of ankle and hindfoot arthrodeses per year Patient demographics Payer types Etiology and clinical success rates following foot and ankle arthrodeses Hospital data-charge data for all costs associated with grafting were anonymously collected for each institution- wer
Slide 9: Materials and Methods: Assumptions
Assumptions General anesthesia utilized in all patients when accounting for additional time charges Material used for graft site backfill-allograft chips Material used for extender-DBM 50 % (ICBG) of patients require 21 additional days of pain meds due to graft site @ $3.76 per pill Complication ana
Slide 10: Results: Autograft and fusion procedures per year
Results Number of Autograft Procedures Performed Per Year (For Foot/Ankle Fusion) Mean (SD) Proximal Tibia 32.5 (30.3) Calcaneus 19.1 (22.0) Distal Tibia 13.6 (21.5) Iliac Crest 5.0 (7.8) Other 1.2 (3.8) Number of Foot/Ankle Fusion Procedures Performed Per Year Mean (SD) Ankle 21.6 (11.1) Hindfoot 3
Slide 11: Results: Patient demographics and insurance
Results Characteristic Mean (SD) Patient average age, years 50.7 (9.2) Patient gender, percent male 58.3 (12.0) Patient insurance type, percent of patients Commercial insurance 66.0 (15.0) Medicare 22.9 (10.1) Indemnity 4.0 (9.3) Medicaid 1.9 (3.2) Self-pay 1.3 (3.1) Uninsured 0.2 (0.6) Other 3.7 (7
Slide 12: Results: Diagnosis and clinical success rates
Results Characteristic Mean (SD) Diagnosis, percent of patients Post-traumatic injury/deformity 57.0 (21.4) Primary arthritis 29.1 (17.6) Rheumatoid arthritis 9.8 (6.8) Other 4.1 (5.6) Estimated clinical success rate † , percent of patients Ankle arthrodesis 92.8 (7.4) Hindfoot arthrodesis 90.6 (6.3
Slide 13: Results: Medical resource use
Results Mean (SD) Medical Resource Iliac Crest (N=7) Local Donor Site (N=10) Operating room time (minutes) 37.9 (17.0) 22.1 (21.6) Recovery room time (minutes) 25.0 (12.3) 3.5 (9.4) Room & board time, inpatient (days) 0.8 (0.6) 0.0 (0.0) Room & board time, outpatient (hours) 0.4 (0.7) % of patients
Slide 14: Results: Hospital Average Cost/Patient
Results-Hospital Average Cost/Patient Iliac Crest Local Graft Cost Driver Inpatient (N=7) Mean (SD) Inpatient (N=9) Mean (SD) Outpatient (N=10) Mean (SD) Operating Room $1,077 (564) $524 (361) $411 (299) Recovery Room $122 (76) $9 (18) $8 (17) Room & Board $522 (489) $0 (0) N/A Anesthesia $121 (101)
Slide 15: Total Direct Medical Costs
Total Direct Medical Costs Iliac Crest Local Graft Medical Resource Inpatient Inpatient Operating Room $1,077 $524 Recovery Room $122 $9 Room & Board $522 $0 Anesthesia $121 $72 Backfill $15 $84 Extender $48 $108 Complications $50 $50 Pain Management $237 $59 Physician Services $231 $211 Total $2,42
Slide 16: Discussion: Prior Studies
Prior Studies Scranton et al Foot Ankle Aug. 2002 Luber et al Foot Ankle Nov. 1998 Charges not costs used to calculate data Single center studies Discussion
Slide 17: Cost driver comparison with Polly (2001)
Cost Driver Abidi (2009) Polly (2001) Key Differences Operating Room $1,077 $540 Increased unit costs Room & Board $522 $231 Increased unit costs Recovery Room $122 $45 Increased unit costs Anesthesia $121 $60 Increased unit costs Bone Graft Harvester N/A $146 Assumed to be included in OR charge Aut
Slide 18: Clinical Significance
Must weigh many factors when deciding between ABG vs. orthobiological device Augment/enhance vs. substitute Time, cost and morbidity associated with ABG Efficacy and cost of Orthobiological devices Currently need to consider Hospital Acquired Conditions (HAC) penalties to surgeon via un- expected re
Slide 19: Conclusions
ABG is associated with significant additional tangible costs to foot and ankle arthrodesis surgery Very little of these costs are attributable to the surgeon Total Direct Increased Cost ICBG-$2423 LBG-$1117 It is very difficult to quantify to human costs attributable to bone grafting such as prolong
BioMimetic Therapeutics — Technical Presentation (July 2010) on 6ix